ACAD
36.99
+0.89
+2.47%
AEMD
0.97
-0.02
-2.02%
APRI
1.79
+0.01
+0.56%
ARNA
26.85
+1.29
+5.05%
ATEC
3.77
+0.06
+1.62%
CNAT
5.1
-0.22
-4.14%
CRXM
0.155
-0.005
-3.125%
CYTX
0.47
+0.012
+2.5322%
DXCM
44.99
+0.02
+0.04%
GNMK
8.11
-0.39
-4.59%
HALO
17.74
-0.12
-0.67%
ILMN
206.48
+0.25
+0.12%
INNV
0.087
-0.003
-2.8090%
INO
6.24
+0.03
+0.48%
ISCO
1.67
+0.04
+2.45%
ISIS
57.56
0.00
0.00%
LGND
142.15
+0.41
+0.29%
LPTN
2.93
-2.93
-100.00%
MBVX
0.73
+0.02
+2.8306%
MEIP
2.33
+0.01
+0.43%
MNOV
6.62
-0.03
-0.45%
MRTX
14.25
+0.55
+4.01%
MSTX
0.13
-0.01
0.00%
NBIX
60.87
-0.27
-0.44%
NUVA
53.71
+1.53
+2.93%
ONCS
1.21
+0.01
+0.83%
ONVO
1.52
+0.04
+2.70%
OREX
1.89
+0.06
+3.28%
OTIC
3.475
-0.125
-3.472%
QDEL
41.36
0.00
0.00%
RCPT
231.96
0.00
0.00%
RGLS
1.32
+0.04
+3.13%
RMD
78.42
+0.69
+0.89%
SCIE
0
0.00
-33.3333%
SPHS
2.28
-0.01
-0.44%
SRNE
2.85
-0.12
-4.20%
TROV
0.79
-0.01
-0.99%
VICL
2.53
-0.33
-11.54%
VOLC
18
0.00
0.00%
ZGNX
38.1
-0.45
-1.17%
ACAD
36.99
+0.89
+2.47%
AEMD
0.97
-0.02
-2.02%
APRI
1.79
+0.01
+0.56%
ARNA
26.85
+1.29
+5.05%
ATEC
3.77
+0.06
+1.62%
CNAT
5.1
-0.22
-4.14%
CRXM
0.155
-0.005
-3.125%
CYTX
0.47
+0.012
+2.5322%
DXCM
44.99
+0.02
+0.04%
GNMK
8.11
-0.39
-4.59%
HALO
17.74
-0.12
-0.67%
ILMN
206.48
+0.25
+0.12%
INNV
0.087
-0.003
-2.8090%
INO
6.24
+0.03
+0.48%
ISCO
1.67
+0.04
+2.45%
ISIS
57.56
0.00
0.00%
LGND
142.15
+0.41
+0.29%
LPTN
2.93
-2.93
-100.00%
MBVX
0.73
+0.02
+2.8306%
MEIP
2.33
+0.01
+0.43%
MNOV
6.62
-0.03
-0.45%
MRTX
14.25
+0.55
+4.01%
MSTX
0.13
-0.01
0.00%
NBIX
60.87
-0.27
-0.44%
NUVA
53.71
+1.53
+2.93%
ONCS
1.21
+0.01
+0.83%
ONVO
1.52
+0.04
+2.70%
OREX
1.89
+0.06
+3.28%
OTIC
3.475
-0.125
-3.472%
QDEL
41.36
0.00
0.00%
RCPT
231.96
0.00
0.00%
RGLS
1.32
+0.04
+3.13%
RMD
78.42
+0.69
+0.89%
SCIE
0
0.00
-33.3333%
SPHS
2.28
-0.01
-0.44%
SRNE
2.85
-0.12
-4.20%
TROV
0.79
-0.01
-0.99%
VICL
2.53
-0.33
-11.54%
VOLC
18
0.00
0.00%
ZGNX
38.1
-0.45
-1.17%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Novogene Establishes First U.S. Genomic Sequencing Center Located at UC Davis; Acquires Second Illumina Hi-Seq X Ten System

April 14, 2016 – 5:00 am

SAN DIEGO, April 14, 2016 /PRNewswire/ — Novogene, a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise, announced today that it has established its first genomics sequencing center in the United States, located on the Sacramento campus of the University of California, Davis. The company also announced that it has purchased its second Illumina Hi-Seq X Ten system — the first system to enable whole human genome sequencing for less than $1,000 — and that it is installing five of these sequencers in the newly established facility at UC Davis.

The purchase of a second Hi-Seq X Ten system adds further to Novogene’s NGS sequencing capacity, among the largest in the world at 36,000 human genomes per year. Novogene was the first company in China to acquire Illumina’s Hi-Seq X Ten system when introduced in early 2014, and has extensive experience using the system to provide­­ whole genome sequencing service. 

Novogene’s genome sequencing center at UC Davis, scheduled to open in early May, will provide to U.S. and global customers high-quality whole genome sequencing and analysis of human, plant and animal samples for biomedical and agricultural research. Novogene’s goal is to establish a CLIA-certified laboratory in the UC Davis facility to enable human genome sequencing for clinical applications as well, including the diagnosis, prevention and treatment of disease. In addition to the ultra-high-throughput Illumina Hi-Seq X instruments, the facility will incorporate other state-of-the-art NGS technologies coupled with Novogene’s cutting-edge bioinformatics and analytical capabilities. In addition to serving the needs of researchers globally, Novogene anticipates that the facility will also benefit UC Davis scientists focused on cancer, regenerative and precision medicine, animal and agricultural research, as well as its broader academic community.

“We are proud to announce the establishment of our first genomic center in the U.S. as well as the acquisition of our second Illumina Hi-Seq X Ten system,” stated Dr. Ruiqiang Li, Founder and Chief Executive Officer of Novogene.  “We look forward to providing U.S.-based NGS services and bioinformatics analyses in support of diverse global genomics research needs. As one of the first and largest users of Illumina’s HiSeq X Ten systems, we are uniquely positioned to rapidly provide customers with the highest quality whole genome sequencing data.”

About Novogene
Novogene Bioinformatics Technology Company, Ltd., headquartered in Beijing with branches in the U.S. and United Kingdom, is a leading genomics solution provider with cutting edge bioinformatics expertise and one of the largest sequencing capacities in the world. Committed to quality service and scientific excellence, Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. The company has completed nearly 10,000 projects and sequenced 140,000-plus samples for more than 6,000 global customers, with research findings published by top-ranked journals such as Science and Nature. Novogene is the first company in China to purchase Illumina’s HiSeq X Ten system and is the only Illumina Genome Network partner in China. Novogene Corporation is Novogene’s U.S. subsidiary, based in San Diego, CA. Please see http://en.novogene.com for more information.

Media Contact: 
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

 

SOURCE Novogene Corporation

Novogene Establishes First U.S. Genomic Sequencing Center Located at UC Davis; Acquires Second Illumina Hi-Seq X Ten System

April 14, 2016 – 5:00 am

SAN DIEGO, April 14, 2016 /PRNewswire/ — Novogene, a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise, announced today that it has established its first genomics sequencing center in the United States, located on the Sacramento campus of the University of California, Davis. The company also announced that it has purchased its second Illumina Hi-Seq X Ten system — the first system to enable whole human genome sequencing for less than $1,000 — and that it is installing five of these sequencers in the newly established facility at UC Davis.

The purchase of a second Hi-Seq X Ten system adds further to Novogene’s NGS sequencing capacity, among the largest in the world at 36,000 human genomes per year. Novogene was the first company in China to acquire Illumina’s Hi-Seq X Ten system when introduced in early 2014, and has extensive experience using the system to provide­­ whole genome sequencing service. 

Novogene’s genome sequencing center at UC Davis, scheduled to open in early May, will provide to U.S. and global customers high-quality whole genome sequencing and analysis of human, plant and animal samples for biomedical and agricultural research. Novogene’s goal is to establish a CLIA-certified laboratory in the UC Davis facility to enable human genome sequencing for clinical applications as well, including the diagnosis, prevention and treatment of disease. In addition to the ultra-high-throughput Illumina Hi-Seq X instruments, the facility will incorporate other state-of-the-art NGS technologies coupled with Novogene’s cutting-edge bioinformatics and analytical capabilities. In addition to serving the needs of researchers globally, Novogene anticipates that the facility will also benefit UC Davis scientists focused on cancer, regenerative and precision medicine, animal and agricultural research, as well as its broader academic community.

“We are proud to announce the establishment of our first genomic center in the U.S. as well as the acquisition of our second Illumina Hi-Seq X Ten system,” stated Dr. Ruiqiang Li, Founder and Chief Executive Officer of Novogene.  “We look forward to providing U.S.-based NGS services and bioinformatics analyses in support of diverse global genomics research needs. As one of the first and largest users of Illumina’s HiSeq X Ten systems, we are uniquely positioned to rapidly provide customers with the highest quality whole genome sequencing data.”

About Novogene
Novogene Bioinformatics Technology Company, Ltd., headquartered in Beijing with branches in the U.S. and United Kingdom, is a leading genomics solution provider with cutting edge bioinformatics expertise and one of the largest sequencing capacities in the world. Committed to quality service and scientific excellence, Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. The company has completed nearly 10,000 projects and sequenced 140,000-plus samples for more than 6,000 global customers, with research findings published by top-ranked journals such as Science and Nature. Novogene is the first company in China to purchase Illumina’s HiSeq X Ten system and is the only Illumina Genome Network partner in China. Novogene Corporation is Novogene’s U.S. subsidiary, based in San Diego, CA. Please see http://en.novogene.com for more information.

Media Contact: 
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

 

SOURCE Novogene Corporation

Zavante Initiates The ZEUS Study For ZTI-01 For The Treatment Of Complicated Urinary Tract Infections

April 14, 2016 – 5:00 am

The pivotal registration study is designed to demonstrate efficacy and safety of ZTI-01 (fosfomycin for injection) in combating serious infections including those related to multidrug-resistant pathogens

SAN DIEGO, April 14, 2016 /PRNewswire/ — Zavante Therapeutics, Inc., a privately held, late clinical-stage biopharmaceutical company, today announced that it has initiated the ZEUS (ZTI-01 Efficacy and Safety) study. ZEUS is a pivotal clinical study for ZTI-01 (fosfomycin for injection), an antibiotic designed to treat hospitalized patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).  ZTI-01, the Company’s lead product candidate, is a first-in-class, broad spectrum I.V. antibiotic under development to treat serious infections, including those caused by multidrug-resistant (MDR) pathogens. The Company expects to complete the ZEUS study in the second half 2017.

“Initiation of our pivotal study for ZTI-01 is an important milestone for Zavante and demonstrates the implementation expertise of our management team,” said Ted Schroeder, founder, president and CEO of Zavante. “The closing of our Series A financing has provided us with financial resources that we believe will be sufficient to initiate and complete the ZEUS study, with a goal of filing a New Drug Application, or NDA, for ZTI-01 with the U.S. Food and Drug Administration (FDA) late in the second half of 2017. We are excited to introduce ZTI-01 as a new class of injectable antibiotics that we hope will be a valuable tool for physicians in the U.S. fighting serious infections including those caused by multidrug-resistant pathogens in the hospital setting.”  

ZEUS is a multi-national, randomized, active-controlled, double-blind study that is expected to provide substantive data to support the use of ZTI-01 to address the unmet medical need of treating cUTI, including patients with MDR infections. It is anticipated that approximately 110 clinical sites will participate in the study to enroll 460 hospitalized patients with cUTI, including AP. ZEUS is the single pivotal study intended to support an NDA for ZTI-01 in the U.S. The study is titled “Multi-center, randomized, double-blind, comparative study to evaluate the safety and efficacy of ZTI-01 vs. piperacillin/tazobactam in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults.”

“The lack of available and effective antibiotics for these life threatening multidrug-resistant pathogens has created an important unmet medical need that is widely acknowledged by national medical agencies and societies,” said George Drusano, M.D., professor of medicine and director of the Institute for Therapeutic Innovation, Department of Medicine in the College of Medicine at the University of Florida.  “An antibiotic with a unique mechanism of action like ZTI-01 would be an important addition to our antibacterial armamentarium when treating seriously ill patients in the hospital.   For the most seriously ill patients, the potential for ZTI-01 to interact positively in combination with antibiotics of other classes is a real plus.”

ZTI-01 is a first-in-class injectable epoxide antibiotic that has demonstrated a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR bacterial strains, for which current antibiotic therapeutic choices are severely limited. In September 2014, the FDA initially granted Qualified Infectious Disease Product (QIDP) designation for ZTI-01 for the indication of cUTI. In December 2015, the FDA expanded the QIDP designations for ZTI-01 to include complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP), and acute bacterial skin and skin structure infections (ABSSSI). Additionally, the FDA granted fast-track designations for all four QIDP designations. These QIDP designations make ZTI-01 eligible for certain incentives available for the development of new antibiotics, including priority FDA review and an additional five-years of market exclusivity under the Generating Antibiotic Incentives Now (GAIN) Act.

About Zavante Therapeutics, Inc.

Zavante is a privately-held, late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing novel products that address serious unmet medical needs in the hospital.

Additional information is available at www.zavante.com.

ZAVANTE and ZAVANTE THERAPEUTICS are registered trademarks of Zavante Therapeutics, Inc.

Logo – http://photos.prnewswire.com/prnh/20151215/296383LOGO

 

SOURCE Zavante Therapeutics, Inc.

Zavante Initiates The ZEUS Study For ZTI-01 For The Treatment Of Complicated Urinary Tract Infections

April 14, 2016 – 5:00 am

The pivotal registration study is designed to demonstrate efficacy and safety of ZTI-01 (fosfomycin for injection) in combating serious infections including those related to multidrug-resistant pathogens

SAN DIEGO, April 14, 2016 /PRNewswire/ — Zavante Therapeutics, Inc., a privately held, late clinical-stage biopharmaceutical company, today announced that it has initiated the ZEUS (ZTI-01 Efficacy and Safety) study. ZEUS is a pivotal clinical study for ZTI-01 (fosfomycin for injection), an antibiotic designed to treat hospitalized patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).  ZTI-01, the Company’s lead product candidate, is a first-in-class, broad spectrum I.V. antibiotic under development to treat serious infections, including those caused by multidrug-resistant (MDR) pathogens. The Company expects to complete the ZEUS study in the second half 2017.

“Initiation of our pivotal study for ZTI-01 is an important milestone for Zavante and demonstrates the implementation expertise of our management team,” said Ted Schroeder, founder, president and CEO of Zavante. “The closing of our Series A financing has provided us with financial resources that we believe will be sufficient to initiate and complete the ZEUS study, with a goal of filing a New Drug Application, or NDA, for ZTI-01 with the U.S. Food and Drug Administration (FDA) late in the second half of 2017. We are excited to introduce ZTI-01 as a new class of injectable antibiotics that we hope will be a valuable tool for physicians in the U.S. fighting serious infections including those caused by multidrug-resistant pathogens in the hospital setting.”  

ZEUS is a multi-national, randomized, active-controlled, double-blind study that is expected to provide substantive data to support the use of ZTI-01 to address the unmet medical need of treating cUTI, including patients with MDR infections. It is anticipated that approximately 110 clinical sites will participate in the study to enroll 460 hospitalized patients with cUTI, including AP. ZEUS is the single pivotal study intended to support an NDA for ZTI-01 in the U.S. The study is titled “Multi-center, randomized, double-blind, comparative study to evaluate the safety and efficacy of ZTI-01 vs. piperacillin/tazobactam in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults.”

“The lack of available and effective antibiotics for these life threatening multidrug-resistant pathogens has created an important unmet medical need that is widely acknowledged by national medical agencies and societies,” said George Drusano, M.D., professor of medicine and director of the Institute for Therapeutic Innovation, Department of Medicine in the College of Medicine at the University of Florida.  “An antibiotic with a unique mechanism of action like ZTI-01 would be an important addition to our antibacterial armamentarium when treating seriously ill patients in the hospital.   For the most seriously ill patients, the potential for ZTI-01 to interact positively in combination with antibiotics of other classes is a real plus.”

ZTI-01 is a first-in-class injectable epoxide antibiotic that has demonstrated a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR bacterial strains, for which current antibiotic therapeutic choices are severely limited. In September 2014, the FDA initially granted Qualified Infectious Disease Product (QIDP) designation for ZTI-01 for the indication of cUTI. In December 2015, the FDA expanded the QIDP designations for ZTI-01 to include complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP), and acute bacterial skin and skin structure infections (ABSSSI). Additionally, the FDA granted fast-track designations for all four QIDP designations. These QIDP designations make ZTI-01 eligible for certain incentives available for the development of new antibiotics, including priority FDA review and an additional five-years of market exclusivity under the Generating Antibiotic Incentives Now (GAIN) Act.

About Zavante Therapeutics, Inc.

Zavante is a privately-held, late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing novel products that address serious unmet medical needs in the hospital.

Additional information is available at www.zavante.com.

ZAVANTE and ZAVANTE THERAPEUTICS are registered trademarks of Zavante Therapeutics, Inc.

Logo – http://photos.prnewswire.com/prnh/20151215/296383LOGO

 

SOURCE Zavante Therapeutics, Inc.

Cydan, NEA’s Orphan Drug Accelerator, Targets Sickle Cell With Startup Imara

April 14, 2016 – 4:25 am

Cydan Development, New Enterprise Associates’s orphan drug startup accelerator, has taken a look at around 600 assets since it was formed some three years ago. Sifting through all these potential…

[[Click headline to continue reading.]]

Sorrento to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

April 14, 2016 – 4:00 am

SAN DIEGO, April 14, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today 3 poster presentations at the upcoming AACR Annual Meeting 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA, April 16 – 20, 2016.

Data to be presented include in vitro studies of an anti-5T4 antibody drug conjugate (ADC), mechanistic studies of a co-stimulatory anti-TIM3 antibody, and preclinical studies of an anti-c-Met ADC in non-small cell lung cancer models.

Abstract Number: 1214
Presentation Title: Development of anti-5T4 antibody-drug conjugates, ZV05-ADCs for targeted cancer therapy in different type of cancers
Session Category: Experimental and Molecular Therapeutics
Session Date and Time: Monday Apr 18, 2016 8:00 AM – 12:00 PM
Location: Convention Center, Halls G-J, Poster Section 15
Author Block: Zhaohui Li*, Hong Zhang#, Dylan Deng#, Tong Zhu#, Gang Chen#, Sheldon Cao*, David Miao#, *Zova Biotherapeutics, Inc., Hangzhou, Zhejiang, PR China, #Sorrento Therapeutics, Inc., San Diego, CA

Abstract Number: 3214  
Presentation Title: A Fully Human Anti-TIM3 Antibody with Co-Stimulatory Activity
Session Category: Immune Checkpoints 2
Session Date and Time: Tuesday Apr 19, 2016 8:00 AM12:00 PM
Location: Convention Center, Halls G-J, Poster Section 25
Author Block: J Dixon Gray, Irina Krapf, Heyue Zhou, Gunnar F. Kaufmann. Sorrento Therapeutics, Inc., San Diego, CA

Abstract Number: 3897  
Presentation Title: A novel c-Met targeting antibody drug conjugate for NSCLC
Session Category: Cancer Chemistry
Session Date and Time: Tuesday Apr 19, 2016 1:00 PM – 5:00 PM
Location: Convention Center, Halls G-J, Poster Section 21
Author Block: Lingna Li, Katherine Fells, Julia Guo, Pia Muyot, Edwige Gros, Yanliang Zhang, Yingqing Sun, Hong Zhang, Yanwen Fu, Tong Zhu, Jian Cao, Gunnar F. Kaufmann,
Gang Chen, Zhenwei Miao. Sorrento Therapeutics, Inc., San Diego, CA

About Sorrento Therapeutics, Inc. 

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento’s lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about Sorrento’s and its subsidiaries’ prospects; Sorrento’s expectations for its technologies and collaborations; Sorrento’s and its subsidiaries’ advances made in developing antibody drug conjugates (ADCs), human monoclonal antibodies using its proprietary G-MAB fully human antibody technology and any of their other respective technologies, if any; and other matters that are described in Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2015, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

© 2016 Sorrento Therapeutics, Inc.  All Rights Reserved.

Logo – http://photos.prnewswire.com/prnh/20150105/167173LOGO

 

SOURCE Sorrento Therapeutics, Inc.

Sorrento to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

April 14, 2016 – 4:00 am

SAN DIEGO, April 14, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today 3 poster presentations at the upcoming AACR Annual Meeting 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA, April 16 – 20, 2016.

Data to be presented include in vitro studies of an anti-5T4 antibody drug conjugate (ADC), mechanistic studies of a co-stimulatory anti-TIM3 antibody, and preclinical studies of an anti-c-Met ADC in non-small cell lung cancer models.

Abstract Number: 1214
Presentation Title: Development of anti-5T4 antibody-drug conjugates, ZV05-ADCs for targeted cancer therapy in different type of cancers
Session Category: Experimental and Molecular Therapeutics
Session Date and Time: Monday Apr 18, 2016 8:00 AM – 12:00 PM
Location: Convention Center, Halls G-J, Poster Section 15
Author Block: Zhaohui Li*, Hong Zhang#, Dylan Deng#, Tong Zhu#, Gang Chen#, Sheldon Cao*, David Miao#, *Zova Biotherapeutics, Inc., Hangzhou, Zhejiang, PR China, #Sorrento Therapeutics, Inc., San Diego, CA

Abstract Number: 3214  
Presentation Title: A Fully Human Anti-TIM3 Antibody with Co-Stimulatory Activity
Session Category: Immune Checkpoints 2
Session Date and Time: Tuesday Apr 19, 2016 8:00 AM12:00 PM
Location: Convention Center, Halls G-J, Poster Section 25
Author Block: J Dixon Gray, Irina Krapf, Heyue Zhou, Gunnar F. Kaufmann. Sorrento Therapeutics, Inc., San Diego, CA

Abstract Number: 3897  
Presentation Title: A novel c-Met targeting antibody drug conjugate for NSCLC
Session Category: Cancer Chemistry
Session Date and Time: Tuesday Apr 19, 2016 1:00 PM – 5:00 PM
Location: Convention Center, Halls G-J, Poster Section 21
Author Block: Lingna Li, Katherine Fells, Julia Guo, Pia Muyot, Edwige Gros, Yanliang Zhang, Yingqing Sun, Hong Zhang, Yanwen Fu, Tong Zhu, Jian Cao, Gunnar F. Kaufmann,
Gang Chen, Zhenwei Miao. Sorrento Therapeutics, Inc., San Diego, CA

About Sorrento Therapeutics, Inc. 

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento’s lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about Sorrento’s and its subsidiaries’ prospects; Sorrento’s expectations for its technologies and collaborations; Sorrento’s and its subsidiaries’ advances made in developing antibody drug conjugates (ADCs), human monoclonal antibodies using its proprietary G-MAB fully human antibody technology and any of their other respective technologies, if any; and other matters that are described in Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2015, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

© 2016 Sorrento Therapeutics, Inc.  All Rights Reserved.

Logo – http://photos.prnewswire.com/prnh/20150105/167173LOGO

 

SOURCE Sorrento Therapeutics, Inc.

EnsoData Raises $550K to Develop Software That Analyzes Sleep Data

April 13, 2016 – 3:45 pm

At an event last August featuring pitches from startups, EnsoData co-founder Chris Fernandez told audience members that his company was hoping to raise $300,000 in a seed funding round. EnsoData,…

[[Click headline to continue reading.]]

Biocom Congratulates Congressman Scott Peters on BIO Legislator of the Year Award

April 13, 2016 – 12:31 pm

SAN DIEGO, April 13, 2016 /PRNewswire/ — Today, Biocom, the association representing the Southern California life science community, joined the Biotechnology Innovation Organization (BIO) and other California life science organizations in presenting U.S. Representative Scott Peters (D-San Diego) with a BIO Legislator of the Year Award.

“Congressman Scott Peters is well deserving of the award, having been a champion for the biotechnology community here in California and throughout the country,” said Joe Panetta, president and CEO of Biocom. “Representative Peters has distinguished himself by supporting policies that foster innovation, including increasing NIH funding, protecting our U.S. patent system, promoting an industry-friendly tax environment and advocating for science-based regulations. He also co-founded the Congressional Life Science Caucus with Congressman Leonard Lance (R-NJ) at the end of last year and is a great supporter of this industry that is one of Southern California’s economic cornerstones.”

Scott Peters, the only lawmaker to have received Biocom’s Legislator of the Year Award three times, received the award in conjunction with today’s BIO Legislative Day Fly-In, which brings together more than 200 biotechnology industry representatives from over 40 states to discuss pressing issues affecting the life science community. Biocom participated in both the Fly-In and the award presentation. Congressman Peters received Biocom’s Legislator of the Year Award in 2008 (as President of the San Diego City Council), 2014, and 2015.

About Biocom

Biocom is one of the largest regional life science associations in the world, representing more than 750 member companies in Southern California. The association focuses on initiatives that position the region’s life science industry competitively on the world stage, and on the development and delivery of innovative products that improve health and quality of life. For more information on Biocom or the Southern California biotechnology and medical device community, please visit the organization’s Web site at http://www.biocom.org or call (858) 455-0300. Follow us on Facebook, LinkedIn, Instagram, and Twitter @BIOCOMCA.

Biocom Media Contact:
Heidi Chokeir
Canale Communications
heidi@canalecomm.com
(619) 849-5377         

Photo – http://photos.prnewswire.com/prnh/20160413/355084

 

                 

SOURCE Biocom

Gritstone Oncology Appoints Dr. Karin Jooss as Chief Scientific Officer

April 13, 2016 – 7:00 am

— Company leadership also expands with hire of Dr. Mojca Skoberne as senior director of Immunology —

EMERYVILLE, Calif., April 13, 2016 /PRNewswire/ — Gritstone Oncology, a cancer immunotherapy company developing next-generation, personalized cancer therapeutics, today announced the appointment of Karin Jooss, Ph.D., as chief scientific officer. Dr. Jooss joins Gritstone from Pfizer, where she served as head of Cancer Immunotherapeutics and Immunopharmacology for seven years.

“We are thrilled that Karin has chosen to join Gritstone at this vital stage and help us build a best-in-class neo-antigen cancer vaccine company,” said Andrew Allen, M.D., Ph.D., Gritstone Oncology co-founder, president and CEO. “She is a seasoned researcher with highly relevant scientific experience, an extensive cancer immunotherapy network, and a proven ability to lead cross-functional teams that effectively move cancer vaccines into clinical development.”

Dr. Jooss has more than 20 years of experience in oncology and immunology research. While at Pfizer, she built and led immuno-oncology teams within the Vaccine Immunotherapeutics department, was a member of the Vaccine Immunotherapeutics leadership team and served as the head of the Immunophamacology team. Her duties included overseeing the assessment of all cancer vaccine in-licensing opportunities, and launching Pfizer’s first clinical cancer-vaccine program deploying a variety of vaccine platforms and immune modulators to build a multi-component vaccine-based immunotherapy regimen. Prior to joining Pfizer, Dr. Jooss served as vice president of Research at Cell Genesys, Inc.

“I am very excited to be joining this innovative and fast-moving team,” said Jooss. “The science of tumor-specific neo-antigens is foundational to cancer immunotherapy, and I am delighted to be able to apply my skills and experience to this new domain alongside the founders and scientists of Gritstone.”

Gritstone also announced today that Mojca Skoberne, Ph.D. has joined the company as senior director of Immunology, reporting to Dr. Jooss. Dr. Skoberne most recently served as program lead at Genocea Biosciences, a company that identifies targets of T cell responses, where she worked up through the ranks of immunology science, building skills including comprehensive T cell characterization and robust, clinical-grade immune-assay development.

“Our goal is to build a powerhouse team that can successfully address the challenges of tumor-specific neoantigen identification and the development of vaccines containing these novel antigens,” said Allen. “The addition of Karin and Mojca to our team fills out our capabilities such that we can continue to move aggressively toward the clinic.”

About Gritstone Oncology
Gritstone Oncology is a privately-held cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and deep financial backing to tackle fundamental challenges at the intersection of cancer genomics, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. Gritstone Oncology is headquartered in the San Francisco Bay Area with certain key functions located in Cambridge, MA. The company launched in October 2015 with a Series A financing of $102 million from leading, blue-chip biotechnology investors, including Versant Ventures, The Column Group and Clarus Ventures. More information can be found at www.gritstoneoncology.com.

Media Contact:
Michele Parisi
925-429-1850
mparisi@forwardhealthinc.com

Photo – http://photos.prnewswire.com/prnh/20160412/354378  

 

SOURCE Gritstone Oncology